Ongoing Assessments & Recent Research.
Easy access to our work
IgA Nephropathy
Feb 2026Smoking Cessation
Jan 2026Non-Cystic Fibrosis Bronchiectasis
Sep 2025Obesity Management
Nov 2025Spinal Muscular Atrophy
Aug 2025Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review to Assess Therapies for IgA Nephropathy
Report will be subject of CTAF meeting in February 2026; Draft Scoping Document open to public comment until August 20, 2025.
07/31/2025Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis
Public comment period now open until August 19, 2025; Requests to make oral comment during public meeting also being accepted.
07/23/2025Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Spinal Muscular Atrophy
There are many remaining uncertainties around the best management of SMA; ICER estimates that a new therapy for some patients with SMA, apitegromab, would achieve common thresholds of cost-effectiveness if priced between $4,600 and $30,200 per year.
07/17/2025Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Examining Strategies to Ensure Affordable Access for Obesity Medications
ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.
Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.